With a market capitalization (market cap) of $1.11B — a measure of how much the company is worth — Amphastar Pharmaceuticals, Inc. ranks #2,424 among the 2,494 companies tracked, and 338th in Healthcare as of October 19, 2026. Shares trade at $26.03, up 0.59% on the day.
of 2,494 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 19, 2026. Ranking headline cap is the snapshot figure as of October 19, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 19, 2026 | $1.14B | -6.11% | $26.23 |
| 2025 | Dec 31, 2025 | $1.21B | -31.39% | $26.78 |
| 2024 | Dec 31, 2024 | $1.77B | -40.36% | $37.13 |
| 2023 | Dec 29, 2023 | $2.97B | +119.18% | $61.85 |
Ranking figure $1.11B as of October 19, 2026.
Amphastar Pharmaceuticals, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $26.20 as of October 19, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.14B on October 19, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 46,743,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $1.22B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.18T | -0.68% |
| #21 | Johnson & Johnson JNJ | $611.17B | -0.76% |
| #23 |
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 19, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is worth $1.11B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Amphastar Pharmaceuticals, Inc.’s book equity is about $788.81M. Market cap is the market value of the outstanding shares. As of October 19, 2026, its market cap is $1.11B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Amphastar Pharmaceuticals, Inc. ranks #2,424 among the 2,494 companies tracked on MarketCapLens. In Healthcare it ranks #338 of 354.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 |
|---|
| Dec 30, 2022 |
| $1.35B |
| +20.71% |
| $28.02 |
| 2021 | Dec 31, 2021 | $1.12B | — | $23.29 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $501.72B |
| -0.54% |
| #32 | UnitedHealth Group Incorporated UNH | $361.39B | +0.31% |
| #33 | Merck & Co., Inc. MRK | $356.8B | -0.91% |
| #45 | Novartis AG NVS | $285.94B | -0.13% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2421 | Piedmont Office Realty Trust, Inc. PDM | $1.12B | -1.71% |
| #2422 | Tennant Company TNC | $1.11B | -0.08% |
| #2423 | JetBlue Airways Corporation JBLU | $1.11B | +0.17% |
| #2425 | Power Solutions International, Inc. PSIX | $1.11B | +4.21% |
| #2426 | VNET Group, Inc. VNET | $1.11B | +0.51% |
| #2427 | Winmark Corporation WINA | $1.1B | -2.31% |
Amphastar Pharmaceuticals, Inc.’s ranking market cap of $1.11B comes from the same snapshot as the rest of this site, as of October 19, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 46,743,000. The historical market-cap series last observed $1.14B on October 19, 2026.
Over the past year, Amphastar Pharmaceuticals, Inc.’s market cap is up 4.61%, using historical market-cap records rather than today’s share count applied to past prices.
Amphastar Pharmaceuticals, Inc. (AMPH) shares trade at $26.03, up 0.59% on the day, as of October 19, 2026.
Amphastar Pharmaceuticals, Inc. trades at a live price-to-earnings (P/E) ratio of 12.5, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.